Cost-effectiveness analysis of 3 different nucleoside drugs for chronic hepatitis B

OBJECTIVE To evaluate the cost-effectiveness of 3 different nucleoside drugs for chronic hepatitis B.METHODS Using pharmacoeconomic cost-effectiveness analysis on 3 different nucleoside drugs(group A of Lamivudine,group B of Adefavir,group C of Entecavir) for 151 cases chronic hepatitis B,were retrospectivly evaluated.RESULTS In unit effect of hepatic-tissue changing,decreasing ALT,HBeAg negative conversion,HBeAg negative canversion in serum and HBV DNA negatire conversion,Entecavir was the best of all.But in cost-effectiveness analysis,the expenses of Lamivudine was lowest of all.CONCLUSION Lamivudine and Adefovir for Chronic Hepatitis B should be chosed preferentially,as well as according to difference of clinical specific indexes.Entecavir could also be used when the money was enough and the other two above-mentioned was unsatisfact.